Clinical Development of a Recombinant Ebola Vaccine in the Midst of an Unprecedented Outbreak

Date/Time: 03 February 2016, 12:00 PM - 1:00 PM
Speaker: Beth-Ann Coller, Ph.D.
Speaker Affiliation: Executive Director, Global Clinical Development, Merck Research Laboratories, North Wales, Pennsylvania
Venue: John A. Burns School of Medicine, Kakaâ??ako Campus, 651 Ilalo Street, MEB Auditorium (Room 315)

For more info: Cori Watanabe 808-692-1654
Description: In November 2014 Merck in-licensed the recombinant, live attenuated rVSVÎ?G-ZEBOV-GP vaccine
originally developed by the Public Health Agency of Canada. The Merck team worked with a large number of partners including NewLink Genetics, WHO, Doctors without Borders, CDC, NIH, the Department of Defense, and BARDA to evaluate the vaccine for safety, immunogenicity, and efficacy in the midst of the largest Ebola outbreak ever. Based on the Phase I, II, and III studies conducted over the course of the last 16 months the vaccine has been shown to be generally well tolerated and immunogenic. Furthermore, the interim analysis from the ring vaccination study conducted by the WHO in Guinea has suggested that the vaccine is efficacious. Given the ongoing threat from this devastating disease, assembling all data and filing for product licensure as quickly as possible remains a critical goal for Merck and our many partners.
Additional Document:Click here to download